ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025
Validation of a cancer population derived AKI machine learning algorithm in a general critical care scenario.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeAcute Kidney Injury (AKI) is the sudden onset of kidney damage. This damage usually comes without warning and can lead to increased mortality and inpatient costs and is of particular significance to patients undergoing cancer treatment. In previous work, we developed a machine learning algorithm to predict AKI up to 30 days prior to the event, trained on cancer patient data. Here, we validate this model on non-cancer data. METHODS/PATIENTS: Medical Information Mart for Intensive Care (MIMIC) is a large, freely available database containing de-identified data from patients who were admitted to the critical care units of the Beth Israel Deaconess Medical Center. Data from 28,498 MIMIC patients were used to validate our algorithm, non-availability of Total Protein measure being the largest removal criterion. RESULTS AND
conclusionsApplying our algorithm to MIMIC data generated an AUROC of 0.821 (95% CI 0.820-0.821) per blood test. Our cancer derived algorithm compares positively with other AKI models derived and/or tested on MIMIC, with our model predicting AKI at the longest time frame of up to 30 days. This suggests that our model can achieve a good performance on patient cohorts very different to those from which it was derived, demonstrating the transferability and applicability for implementation in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.